Centene Co. (NYSE:CNC) Director Thomas Greco Buys 17,000 Shares

Centene Co. (NYSE:CNC) Director Thomas Greco bought 17,000 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were purchased at an average price of $59.75 per share, for a total transaction of $1,015,750.00. Following the purchase, the director now owns 19,309 shares in the company, valued at $1,153,712.75. This represents a 736.25 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Centene Stock Down 0.2 %

NYSE CNC opened at $59.58 on Friday. Centene Co. has a 52 week low of $55.03 and a 52 week high of $81.42. The firm has a market capitalization of $30.08 billion, a price-to-earnings ratio of 10.34, a PEG ratio of 0.78 and a beta of 0.46. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.64. The company has a fifty day moving average of $60.75 and a two-hundred day moving average of $68.20.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CNC. Oppenheimer dropped their price objective on Centene from $95.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday, December 13th. Stephens cut their price objective on shares of Centene from $75.00 to $73.00 and set an “equal weight” rating for the company in a report on Friday, December 13th. Truist Financial lowered their target price on shares of Centene from $89.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $90.00 price target on shares of Centene in a report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and set a $75.00 price objective (down previously from $80.00) on shares of Centene in a report on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $80.92.

Hedge Funds Weigh In On Centene

Several hedge funds have recently added to or reduced their stakes in the company. Park Place Capital Corp boosted its position in shares of Centene by 1,190.0% during the third quarter. Park Place Capital Corp now owns 387 shares of the company’s stock valued at $29,000 after buying an additional 357 shares during the period. WR Wealth Planners LLC boosted its holdings in Centene by 41.4% during the 2nd quarter. WR Wealth Planners LLC now owns 468 shares of the company’s stock valued at $31,000 after acquiring an additional 137 shares during the period. Chris Bulman Inc bought a new position in Centene in the 2nd quarter valued at $33,000. Crewe Advisors LLC increased its stake in Centene by 174.3% in the second quarter. Crewe Advisors LLC now owns 683 shares of the company’s stock worth $45,000 after purchasing an additional 434 shares during the period. Finally, Private Trust Co. NA grew its holdings in shares of Centene by 75.3% in the third quarter. Private Trust Co. NA now owns 773 shares of the company’s stock worth $58,000 after purchasing an additional 332 shares during the last quarter. 93.63% of the stock is currently owned by institutional investors.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.